Ana M. Aparicio
About
Ana M. Aparicio is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Ana M. Aparicio has authored 154 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Pulmonary and Respiratory Medicine, 61 papers in Oncology and 50 papers in Molecular Biology. Recurrent topics in Ana M. Aparicio's work include Prostate Cancer Treatment and Research (97 papers), Prostate Cancer Diagnosis and Treatment (31 papers) and Radiopharmaceutical Chemistry and Applications (25 papers). Ana M. Aparicio is often cited by papers focused on Prostate Cancer Treatment and Research (97 papers), Prostate Cancer Diagnosis and Treatment (31 papers) and Radiopharmaceutical Chemistry and Applications (25 papers). Ana M. Aparicio collaborates with scholars based in United States, Spain and Greece. Ana M. Aparicio's co-authors include Gerda Egger, Peter A. Jones, Gangning Liang, Marc C. Chamberlain, Christopher J. Logothetis, Paul G. Corn, Patricia Troncoso, Sumit K. Subudhi, Padmanee Sharma and Eleni Efstathiou and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.
In The Last Decade
Ana M. Aparicio
144 papers receiving 7.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ana M. Aparicio United States | 39 | 4.1k | 3.1k | 2.3k | 1.5k | 775 | 154 | 7.7k | ||
| Paul G. Corn United States | 42 | 5.1k 1.2× | 3.2k 1.0× | 2.4k 1.0× | 2.1k 1.4× | 435 0.6× | 190 | 8.2k | ||
| Eva Corey United States | 50 | 3.8k 0.9× | 3.9k 1.2× | 3.3k 1.4× | 1.8k 1.2× | 565 0.7× | 194 | 7.9k | ||
| Gregory A. Otterson United States | 58 | 5.1k 1.2× | 3.4k 1.1× | 5.0k 2.2× | 1.8k 1.2× | 692 0.9× | 240 | 10.3k | ||
| Hirotsugu Uemura Japan | 39 | 2.4k 0.6× | 3.9k 1.2× | 2.1k 0.9× | 1.3k 0.9× | 774 1.0× | 367 | 7.1k | ||
| Annick Desjardins United States | 51 | 3.2k 0.8× | 2.2k 0.7× | 2.6k 1.2× | 2.2k 1.4× | 1.4k 1.8× | 247 | 10.0k | ||
| Lisa G. Horvath Australia | 46 | 2.4k 0.6× | 2.5k 0.8× | 2.2k 1.0× | 1.6k 1.1× | 449 0.6× | 198 | 6.0k | ||
| Renato Franco Italy | 50 | 3.4k 0.8× | 1.8k 0.6× | 3.4k 1.5× | 1.6k 1.1× | 1.1k 1.4× | 324 | 8.2k | ||
| W. Kimryn Rathmell United States | 52 | 6.6k 1.6× | 4.6k 1.5× | 2.4k 1.0× | 3.9k 2.5× | 1.1k 1.4× | 232 | 10.3k | ||
| D. Williams Parsons United States | 31 | 5.3k 1.3× | 1.3k 0.4× | 1.9k 0.8× | 3.3k 2.2× | 794 1.0× | 92 | 10.2k | ||
| Anthony Gonçalvès France | 45 | 2.8k 0.7× | 3.0k 1.0× | 6.2k 2.7× | 2.3k 1.5× | 1.4k 1.7× | 318 | 9.5k |
Countries citing papers authored by Ana M. Aparicio
Since
Specialization
Citations
This map shows the geographic impact of Ana M. Aparicio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana M. Aparicio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana M. Aparicio more than expected).
Fields of papers citing papers by Ana M. Aparicio
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ana M. Aparicio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana M. Aparicio. The network helps show where Ana M. Aparicio may publish in the future.
Co-authorship network of co-authors of Ana M. Aparicio
This figure shows the co-authorship network connecting the top 25 collaborators of Ana M. Aparicio. A scholar is included among the top collaborators of Ana M. Aparicio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana M. Aparicio. Ana M. Aparicio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tang, Chad, Alexander D. Sherry, Hyunsoo Hwang, et al.. (2025). World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.. Journal of Clinical Oncology. 43(5_suppl). 15–15.
2.
Sherry, Alexander D., Cara Haymaker, Bryan Fellman, et al.. (2025). Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives.. Journal of Clinical Oncology. 43(5_suppl). 140–140.
3.
Hahn, Andrew W., Ana M. Aparicio, Hossein Jadvar, & Darren M.C. Poon. (2024). MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 28(3). 745–747.
4.
Hahn, Andrew W., Rebecca S. Tidwell, Efstratios Koutroumpakis, et al.. (2023). A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio).. Journal of Clinical Oncology. 41(6_suppl). TPS273–TPS273.
5.
Sherry, Alexander D., Cara Haymaker, Tharakeswara Bathala, et al.. (2023). Peripheral T-Cell Priming and Micrometastatic Disease Control with Metastasis-Directed Therapy: Multidimensional Immunogenomic Profiling of Oligometastatic Prostate Cancer in the EXTEND Trial. International Journal of Radiation Oncology*Biology*Physics. 117(2). S33–S34.
6.
Tidwell, Rebecca S., Miao Zhang, Keyi Zhu, et al.. (2023). Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers. 15(24). 5843–5843.
7.
Ranasinghe, Weranja, Daniel D. Shapiro, Miao Zhang, et al.. (2021). Optimizing the diagnosis and management of ductal prostate cancer. Nature Reviews Urology. 18(6). 337–358.
8.
Davis, John W., Amado J. Zurita, Xuemei Wang, et al.. (2021). Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. European Journal of Cancer. 157. 259–267.
9.
Malihi, Paymaneh D., Ryon P. Graf, Ángel Rodríguez, et al.. (2020). Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clinical Cancer Research. 26(15). 4143–4153.
10.
Kim, Sang T., William A. Murphy, Ana M. Aparicio, & Sumit K. Subudhi. (2020). RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. SHILAP Revista de lepidopterología. 3(3). 128–132.
11.
Tsikkinis, Alexandros, Anh Hoang, Ana M. Aparicio, et al.. (2020). A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 19(1). 22–31.e5.
12.
Subudhi, Sumit K., Luis M. Vence, Hao Zhao, et al.. (2020). Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine. 12(537).
13.
Schlecht, Ulrich, Justin Smith, Sundari Suresh, et al.. (2017). Quantitative analysis of protein interaction network dynamics in yeast. Molecular Systems Biology. 13(7). 934–934.
14.
Varkaris, Andreas, Paul G. Corn, Nila U. Parikh, et al.. (2015). Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clinical Cancer Research. 22(1). 107–121.
15.
Aparicio, Ana M., Li Shen, Elsa Li Ning Tapia, et al.. (2015). Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clinical Cancer Research. 22(6). 1520–1530.
16.
Aparicio, Ana M., Andrea Harzstark, Paul G. Corn, et al.. (2013). Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clinical Cancer Research. 19(13). 3621–3630.
17.
Tzelepi, Vassiliki, Jiexin Zhang, Guanglin Wu, et al.. (2011). Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features. Clinical Cancer Research. 18(3). 666–677.
18.
Jonasch, Eric, Christopher G. Wood, Surena F. Matin, et al.. (2009). Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(25). 4076–4081.
19.
Egger, Gerda, et al.. (2007). Inhibition of Histone Deacetylation Does Not Block Resilencing of p16 after 5-Aza-2′-Deoxycytidine Treatment. Cancer Research. 67(1). 346–353.
20.
Sonpavde, Guru, Ana M. Aparicio, Kristi A. Boehm, et al.. (2007). Phase II Study of Azacitidine to Restore Responsiveness of Prostate Cancer to Hormonal Therapy. Clinical Genitourinary Cancer. 5(7). 457–459.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paul G. Corn Breakdown of academic impact, for papers by Eva Corey Breakdown of academic impact, for papers by Gregory A. Otterson Breakdown of academic impact, for papers by Hirotsugu Uemura Breakdown of academic impact, for papers by Annick Desjardins Breakdown of academic impact, for papers by Lisa G. Horvath Breakdown of academic impact, for papers by Renato Franco Breakdown of academic impact, for papers by W. Kimryn Rathmell Breakdown of academic impact, for papers by D. Williams Parsons Breakdown of academic impact, for papers by Anthony Gonçalvès